Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: A bi‐institutional propensity‐matched cohort study

MLA

Shohei Komatsu, et al. “Hepatectomy versus Sorafenib for Advanced Hepatocellular Carcinoma with Macroscopic Portal Vein Tumor Thrombus: A Bi‐institutional Propensity‐matched Cohort Study.” Journal of Hepato-Biliary-Pancreatic Sciences, vol. 30, Sept. 2022, pp. 303–14. EBSCOhost, https://doi.org/10.1002/jhbp.1236.

APA

Shohei Komatsu, Kazuomi Ueshima, Masahiro Kido, Kaori Kuramitsu, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Yonon Ku, Masatoshi Kudo, & Takumi Fukumoto. (2022). Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: A bi‐institutional propensity‐matched cohort study. Journal of Hepato-Biliary-Pancreatic Sciences, 30, 303–314. https://doi.org/10.1002/jhbp.1236

Chicago

Shohei Komatsu, Kazuomi Ueshima, Masahiro Kido, Kaori Kuramitsu, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Yonon Ku, Masatoshi Kudo, and Takumi Fukumoto. 2022. “Hepatectomy versus Sorafenib for Advanced Hepatocellular Carcinoma with Macroscopic Portal Vein Tumor Thrombus: A Bi‐institutional Propensity‐matched Cohort Study.” Journal of Hepato-Biliary-Pancreatic Sciences 30 (September): 303–14. doi:10.1002/jhbp.1236.